OBJECTIVE: To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine (PRV) on health care encounters in nearly 70 000 subjects randomized in three regions - Europe, the United States, and Latin America/the Caribbean - in the Rotavirus Efficacy and Safety Trial (REST). METHODS:Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED) visits involving rotavirus G-types 1-4 occurring > or =14 days after the third dose of vaccine for up to 2 years. RESULTS: In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States, and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions. CONCLUSIONS:PRV reduced hospitalizations and ED visits within each region in REST. Results were consistent across regions and across the overall study cohort.
RCT Entities:
OBJECTIVE: To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine (PRV) on health care encounters in nearly 70 000 subjects randomized in three regions - Europe, the United States, and Latin America/the Caribbean - in the Rotavirus Efficacy and Safety Trial (REST). METHODS: Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED) visits involving rotavirus G-types 1-4 occurring > or =14 days after the third dose of vaccine for up to 2 years. RESULTS: In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States, and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions. CONCLUSIONS: PRV reduced hospitalizations and ED visits within each region in REST. Results were consistent across regions and across the overall study cohort.
Authors: Julie A Bettinger; Kathryn Wills; Nicole Le Saux; David W Scheifele; Scott A Halperin; Wendy Vaudry Journal: Can J Infect Dis Med Microbiol Date: 2011 Impact factor: 2.471
Authors: Ming Xia; Pengwei Huang; Chen Sun; Ling Han; Frank S Vago; Kunpeng Li; Weiming Zhong; Wen Jiang; John S Klassen; Xi Jiang; Ming Tan Journal: ACS Nano Date: 2018-09-25 Impact factor: 15.881
Authors: Mario Saia; Aurore Giliberti; Giampietro Callegaro; Tatjana Baldovin; Marta Cecilia Busana; Francesco Pietrobon; Chiara Bertoncello; Vincenzo Baldo Journal: BMC Public Health Date: 2010-10-22 Impact factor: 3.295
Authors: Angel Herrera Guerra; Chris Stockmann; Andrew T Pavia; Adam L Hersh; Emily A Thorell; Hsin Yi Weng; Kent Korgenski; Carrie L Byington; Krow Ampofo Journal: J Pediatric Infect Dis Soc Date: 2012-06-22 Impact factor: 3.164